Filing Flows › Rani Therapeutics Holdings (RANI) › Q4 2024
Rani Therapeutics Holdings (RANI) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 31, 2025
Rani Therapeutics Holdings (RANI) reported revenue of $1.0M for the fourth quarter 2024 (Q4 2024).
Rani Therapeutics Holdings, Q4 2024: revenue $1.0M, net loss $15.7M, operating cash flow −$8.7M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.0M | — | — |
| Operating profit | −$15.0M | — | — |
| Net earnings | −$15.7M | — | — |
| Operating cash flow | −$8.7M | — | — |
What changed
Revenue was $1.0M in Q4 2024.
Operating costs exceeded revenue by $15.0M, an operating margin of -1455.1%. The quarter ended with a net loss of $15.7M. Minority interests bore $6.8M of it: to shareholders the quarter was a loss of $8.9M.
Operating cash flow was −$8.7M. Non-cash charges added back $266K of depreciation and amortization and $4.0M of share-based compensation. Working capital and other items added $2.8M. Capital expenditures of $31K exceeded it, leaving free cash flow of −$8.7M.
Questions
What was Rani Therapeutics Holdings' revenue in the fourth quarter 2024?
Rani Therapeutics Holdings (RANI) reported revenue of $1.0M for the fourth quarter 2024 (Q4 2024).